Advertisement

Topics

Companies Related to "Efficacy and Safety of Empagliflozin (BI 10773) in Patients With Type 2 Diabetes and Renal Impairment" [Most Relevant Company Matches] - Page: 2 RSS

18:11 EDT 18th March 2019 | BioPortfolio

Here are the most relevant search results for "Efficacy and Safety of Empagliflozin (BI 10773) in Patients With Type 2 Diabetes and Renal Impairment" found in our extensive corporate database of over 50,000 company records.

Showing "Efficacy Safety Empagliflozin 10773 Patients With Type Diabetes" Companies 26–50 of 5,800+

Relevant

Avaxia Biologics, Inc.

Avaxia is a leader in the growing field of gut-targeted therapeutics — orally administered, minimally absorbed drugs that are designed to act locally in the gastrointestinal tract. Avaxia’s lead clinical candidate, AVX-470, is an oral anti-TNF antibody for inflammatory bowel disease. This transformative product offers potentially improved safety and ...


Semma Therapeutics

Semma Therapeutics was founded to develop transformative therapies for Type 1 diabetes patients. Recent work in the laboratory of Professor Douglas Melton led to the discovery of a method to generate billions of functional, insulin-producing beta cells in the laboratory. This breakthrough technology has been exclusively licensed to Semma Therapeutics for t...

POXEL S.A.

Poxel uses its development expertise in metabolism to advance a pipeline of drug candidates focused on the treatment of metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH). We have successfully completed the Phase 2 clinical program for our first-in-class lead product, Imeglimin, which targets mitochondrial dysfunction, ...


GI Dynamics, Inc.

GI Dynamics is focused on the development and commercialization of effective, non-surgical treatments for type 2 diabetes and obesity. The company’s patented EndoBarrier® technology has the potential to deliver effective treatments for people combating weight problems and diabetes or diabetes risk factors.

Glucose Health, Inc.

Glucose Health, Inc. dietary products engage the large and growing market of consumers aware of the seriousness of Type 2 diabetes and proactively seeking natural blood sugar health solutions. The CDC currently estimates 2 in 5 adults – 86 million Americans – will develop Type 2 diabetes in their lifetime. Glucose Health, Inc. dietary products ar...

Diabetes & Glandular Disease Clinic of San Antonio

The Diabetes & Glandular Disease Clinic, P.A. (DGD) offers the best in treatment for hormonal and metabolic disorders such as type 1 and 2 diabetes, gestational diabetes, thyroid disease, osteoporosis, lipid disorders (high cholesterol), pituitary/adrenal gland problems, menstrual disorders and hirsutism (excessive facial hair on women). All our doctors are board-certified in Endocrinology & Metab...

Akesis Pharmaceuticals

Akesis Pharmaceuticals is an emerging diabetes company with unique, patent-protected products that combine approved prescription drugs with the pure trace minerals chromium and vanadium. Early clinical studies have shown that the combination of these products lowers blood glucose levels in type 2 diabetes patients more substantially than the prescription drugs, including metformin, alone. Akesis...

Betagenon AB

Betagenon has secured a strong, proprietary technology platform based upon the extensive research expertise on type 2 diabetes disease mechanisms established by the Founders, leading experts in the field. Betagenon's vision is to become a frontier company that delivers new smart drug platform solutions to the pharmaceutical industry for treatment of the metabolic syndrome and diabetes type 2. Afte...

MannKind Corporation

MannKind Corporation (Nasdaq:MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes and cancer. Its diabetes pipeline includes AFREZZA(TM) and MKC253. MKC253 is currently in phase 1 clinical trials. In March 2009, MannKind submitted a New Drug Application (NDA) to the U.S. Food ...

Thrive365

Thrive365 is a patented food scoring system designed specifically for people with non-insulindependent type 2 diabetes or pre-diabetes to empower them to build a diet that aligns with nutrition recommendations for people with diabetes. Backed by $10 million in research and development over the past six years, the Thrive365 food scoring system is available ...

KeyVive.com

KeyVive (pronounced "key veev") derives from the French term "qui vive" and means "one who lives." The mission of KeyVive is to help people affected by diabetes succeed in living a healthy life by educating, informing and connecting individuals to each other. The Web site concept was conceived by Aimee and David Greenholtz as part of their effort to support those affected by diabetes. Aimee was di...

ADVANCED VIRAL RESEARCH CORP

Advanced Viral Research Corp. (OTC Bulletin Board: ADVR), established in the mid-1980s, and headquartered in Yonkers, New York, is a biopharmaceutical firm dedicated to improving patients' lives by researching, developing, and bringing to market new and effective therapies for many serious diseases and disorders. With the commitment of expert leadership and skilled research scientists, ADVR is ag...

Kepivance™ (palifermin)

Kepivance™ (palifermin) is indicated to decrease the incidence and duration of severe oral mucositis (mouth sores) in patients withhematologic (blood) cancers undergoing high-dose chemotherapy, with or without radiation, followed by bone marrow transplant. The safety and efficacy of Kepivance™ have not been established in patients with nonhematologic malignancies.

Bigfoot Biomedical, Inc.

Bigfoot Biomedical was founded by a team of people with a personal connection to type 1 diabetes and, with its Loop and Inject services, seeks to change the paradigm of care for insulin-requiring diabetes by leveraging data, connectivity, automation, and machine learning to reduce the burden on people with insulin-requiring diabetes and maximize the levera...

InVasc Therapeutics, Inc.

InVasc Therapeutics, Inc., headquartered in Tucker, Georgia, is a biopharmaceutical company developing drugs to mitigate risks associated with cardiometabolic diseases. Cardiovascular and metabolic diseases such as diabetes, hypertension, stroke and dyslipidemia are the leading causes of morbidity and mortality worldwide. The Company plans to file an IND l...

Zucara Therapeutics

Zucara Therapeutics, a spin-off company by The Centre for Drug Research and Development (CDRD) and MaRS Innovation (MI), is developing the first drug therapy to prevent hypoglycemia in people with diabetes. The Company’s first-in-class therapeutic is aimed at inhibiting a hormone in the pancreas called somatostatin, which does not function properly in ...

Population Diagnostics, Inc.

Population Diagnostics, Inc. (PDx, www.populationdiagnostics.com) is applying its discoveries in human genetics to the development of DNA-based diagnostics and personalized medicine tests. PDx’s technology, which reveals the genetic causes of complex diseases such as autism, diabetes, Parkinson’s, and Alzheimer’s, enables development of early ...

GI Dynamics

GI Dynamics is focused on developing effective, non-surgical approaches for treating type 2 diabetes and obesity. The company’s patented EndoBarrier™ Technology has the potential to deliver medical interventions for patients combating weight problems and diabetes or diabetes risk factors. Data from clinical trials demonstrate that the EndoBarr...

Virta Health

Virta is online specialty medical clinic that reverses type 2 diabetes safely and sustainably, without the risks, costs, or side effects of medications or surgery. Drawing on decades of research, including that of our founders and advisors, Virta is driving two major innovations. First, we take a highly individualized approach to metabolic health, focused ...

Apofore Corporation

Apofore Corporation is a focused company founded by Patrick Tso, PhD and funded by HealthCare Ventures. ApoA-IV, the first therapeutic being prepared for clinical trials, has promising pre-clinical data supporting potential use in patients with Type 2 diabetes mellitus. For more information, please visit www.apofore.com.

Galleon Pharmaceuticals

Galleon is the first pharmaceutical company to focus primarily on the drug treatment of breathing-control disorders. Its initial goals are to improve the safety, efficacy and economics associated with the acute care of surgical patients and longer-term care of patients with conditions such as moderate-to-severe pain or sleep apnea. In the United States alo...

Inspired by Diabetes

Inspired by Diabetes is a global campaign asking people moved by the triumphs and challenges of those with diabetes and those who care for them to express their inspiration and share it with others around the world. The program is a collaboration between global champions Eli Lilly and Company, the International Diabetes Federation's (IDF) Unite for Diabetes initiative and the International Society...

Sonus Pharmaceuticals

SONUS PHARMACEUTICALS is focused on the development of drugs that provide better therapeutic alternatives for cancer patients,including improved efficacy,safety and tolerability,and are more convenient to use

Bayer Diabetes Care

Bayer Diabetes Care is a worldwide leader in diabetes care, supporting customers in 100 countries and, for more than 40 years, has led the way in diabetes care product innovation. Today, Bayer Diabetes Care offers an unparalleled choice in diabetes management systems and comprehensive support including education, tools and resources designed to simplify life with diabetes. Bayer Diabetes Care is a...

Diabetes Care Partners

Diabetes Care Partners℠ (DCP) is a nationally recognized comprehensive diabetes solutions company providing all aspects of diabetes management including education, dietetic consultation, behavioral assessment and modification, and pharmacy while coordinating care across the patients’ healthcare team to engage the right patient, at the right tim...


More From BioPortfolio on "Efficacy and Safety of Empagliflozin (BI 10773) in Patients With Type 2 Diabetes and Renal Impairment"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks